JY
VCNX

Jeff Yass’s Vaccinex, Inc. Common Stock VCNX Stock Holding History

Jeff Yass’s Portfolio VCNX Stock Details VCNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-472
Closed -$39.6K – 13383
2023
Q1 		$39.6K Buy
+472
New +$51.8K ﹤0.01% 11801
2022
Q4 		– Sell
-418
Closed -$51.8K – 13973
2022
Q3 		$43K Buy
418
+284
+212% +$55.7K ﹤0.01% 12297
2022
Q2 		$30K Sell
134
-30
-18% -$7.67K ﹤0.01% 12227
2022
Q1 		$46K Buy
164
+59
+56% +$16.3K ﹤0.01% 12349
2021
Q4 		$23K Sell
105
-39
-27% -$14.1K ﹤0.01% 12804
2021
Q3 		$65K Sell
144
-272
-65% -$136K ﹤0.01% 12259
2021
Q2 		$245K Sell
416
-106
-20% -$56.1K ﹤0.01% 11187
2021
Q1 		$327K Buy
+522
New +$336K ﹤0.01% 10424
2020
Q4 		– Sell
-84
Closed -$35.1K – 11859
2020
Q3 		$31K Buy
+84
New +$91.6K ﹤0.01% 10322

Other funds holding VCNX

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Jeff Yass's VCNX Position: Q2 2023 in Review

Jeff Yass sold out of Vaccinex, Inc. Common Stock (VCNX) in Q2 2023, closing a stake of 472 shares — an estimated $39.6K sold.

Jeff Yass first reported a position in VCNX in Q3 2020 and held it in 9 quarters. The position peaked at $327K in Q1 2021. 22 funds tracked by Wall St. Rank hold VCNX as of Q2 2023.

  • Jeff Yass reported no remaining Vaccinex, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Jeff Yass sold 472 Vaccinex, Inc. Common Stock shares in Q2 2023, an estimated $39.6K.
  • Jeff Yass first reported a position in Vaccinex, Inc. Common Stock in Q3 2020 and held it in 9 quarters.
  • Jeff Yass's Vaccinex, Inc. Common Stock position peaked at $327K in Q1 2021.
  • 22 funds tracked by Wall St. Rank held Vaccinex, Inc. Common Stock as of Q2 2023.

Based on Susquehanna International Group's 13F filing for Q2 2023, filed 11 Aug 2023.